MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights
-Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter-
- MEI Maintains Strong Financial Position with ~$164 Million in Cash-
News provided by
Share this article
Share this article
SAN DIEGO, May 6, 2021 /PRNewswire/ MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2021 and highlighted recent corporate progress. The first several months of 2021 have been very eventful for MEI, highlighted by the completion of enrollment in the follicular lymphoma efficacy population arm of the zandelisib TIDAL study. In addition, we recently reported preclinical data at AACR 2021, demonstrating the ability of voruciclib to downregulate MYC and synergize with KRAS inhibitors in KRAS mutant cancers, said Da
MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights
-Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter-
- MEI Maintains Strong Financial Position with ~$164 Million in Cash-
News provided by
Share this article
Share this article
SAN DIEGO, May 6, 2021 /PRNewswire/ MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2021 and highlighted recent corporate progress. The first several months of 2021 have been very eventful for MEI, highlighted by the completion of enrollment in the follicular lymphoma efficacy population arm of the zandelisib TIDAL study. In addition, we recently reported preclinical data at AACR 2021, demonstrating the ability of voruciclib to downregulate MYC and synergize with KRAS inhibitors in KRAS mutant cancers, said Da
MEI Pharma Reports Second Quarter Fiscal Year 2021 Results and Operational Highlights Multiple Clinical Development Milestones Anticipated in 2021 MEI Maintains Strong Financial Position with $180 Million in Cash
News provided by
Share this article
Share this article
SAN DIEGO, Feb. 4, 2021 /PRNewswire/ MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2020. We remain well positioned and focused on advancing zandelisib toward commercialization to deliver an improved therapeutic option to people living with B-cell malignancies, said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. We anticipate multiple important milestones from the zandelisib program this year, including topline data from our Phase 2 TIDAL study in the fourth quarter as we closely monitor for potential negative impacts related to the ongoing COVID 19